Mektovi (binimetinib) — CareFirst (Caremark)
Non-small cell lung cancer (NSCLC)
Initial criteria
- BRAF V600E mutation-positive recurrent, advanced, or metastatic NSCLC in combination with encorafenib (Braftovi) when the member has not experienced disease progression on BRAF-targeted therapy
Reauthorization criteria
- Continued treatment when there is no evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months